Figure 2From: Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antiviralsTreatment cost per SVR (total costs were divided by the corresponding absolute numbers of SVR achieved or expected). NOTE: Cost 1 represents the actual cost incurred for treating the 104 patients under study with Peg-interferon and ribavirin while naĂŻve. Cost 2 represents the estimated cost of a lead-in strategy with PEG-IFN/RBV for 4 weeks, followed by a directly acting antiviral for 12 or 36 weeks in the same patients while naĂŻve. Cost 3 represents the estimated cost of PEG-IFN/RBV in naĂŻve patients (Cost 1) plus PEG-IFN/RBV with addition of a DAA in our patients who did not achieve a SVR.Back to article page